Home / Transcripts / Ultragenyx Pharmaceutical Inc. (RARE) · February 12, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Transcript

February 12, 2026

NASDAQ US Health Care Biotechnology earnings 50 min

Earnings Call Speaker Segments

Joshua Higa executive
#1

Thanks — a press release is out that breaks down our financial results, and it's available on our site, ultragenyx.com. On the line with me today are Chief Executive Officer and President Emil Kakkis, Chief Financial Officer Howard Horn, Chief Commercial Officer Erik Harris, and Chief Medical Officer Eric Crombez. A quick reminder for all of you: forward-looking statements will be part of what we say on today's call. Certain risks and uncertainties apply to those statements, and what we actually achieve could differ materially. We'd point you to the risk factors covered in our most recent SEC filings. Now I'll hand things over to Emil.

Emil Kakkis executive
#2

Thank you, Josh, and good afternoon to all of you. For the company, 2026 looks set to be a major year, since we expect to hit crucial turning points across several programs. Among these are two possible approvals—one in MPS IIIA, or Sanfilippo type A syndrome, and one in glycogen storage disease type Ia—along with a pivotal data readout in Angelman syndrome. These efforts perfectly illustrate our goal of delivering vital first-ever therapies to patients and their families, while at the same time generating substantial long-term worth for shareholders. Only last week, at the World Symposium, we shared updated data from the UX111 for MPS IIIA program. Reflecting another year of follow-up, the fresh data keep showing sustained and notable additional separation among early-treated patients across multiple neurologic endpoints—the Bayley, cognitive, and communication scores among them—relative to the decline seen in MPS IIIA natural history. The data likewise reveal a notable and lasting drop in the toxic substrate heparan sulfate and in other biomarkers caused by the disease, indicating a restoration of lysosomal function, no matter the age or stage of disease; any of a number of different assay methods available can effectively measure this reduction in CSF HS, and every HS measure correlates significantly with stabilization or improvement in clinical function. At a Reagan-Udall convened workshop in 2023, highly trained and qualified academics, clinicians, and industry leaders—the internationally recognized experts in this field—thoroughly discussed, substantiated, and ratified these results in humans and animal models; for the entire UX111 study program, we now have more than 8 years of follow-up, and on the whole, these data continue to support a clinically meaningful and durable clinical effect of UX111, no matter the age or stage of disease, all backed by consistent improvement in multiple relevant direct measures of disease activity, including CSF HS. Late last month, we resubmitted the UX111 BLA to FDA, and earlier today, we received an incomplete response letter. We had provided complete responses to each CRL item, but the FDA is now requiring additional details within supportive documentation on the CMC CRL responses made and their impact; this information is typically provided during an inspection, and we were prepared to do so, but we will now provide this supportive documentation as a part of our BLA resubmission. Our push to bring these transformational therapies to patients is backed by our established and still growing commercial business, which once again delivered significant 20% year-over-year growth in 2025. Today we're bringing treatments to patients in more than 35 countries, every one of which contributed revenue in 2025. As we leverage the investments, expertise, and relationships we have established around the world to commercialize three additional treatments over the next two years, this commercial infrastructure will power our growth into 2026 and beyond. Erik Harris will outline for you our results across programs last year and discuss our vision to expand and deepen our global commercial footprint in the coming years. Earlier today our press release covered this, and after the UX111 CRL we received last year, along with results from the UX143 trials, we reached the decision we had to make: put a strategic restructuring plan in place so that operating expenses come down and our resources line up directly with the opportunities offering the greatest impact ahead. Howard will walk everyone through several specifics shortly, yet these steps had to be taken so that we remain on track to reach profitability in 2027 and continue moving forward a pipeline of new products that matters.

Howard Horn executive
#3

Thanks, Emil, and good afternoon to all of you. Before I walk through our financial results and outlook, I'd like to say more about what our strategic restructuring plan is meant to accomplish. This plan directs our people and spending toward the value drivers that matter most in the near term, and at the same time it trims internal and external costs in areas throughout the company, such as manufacturing, clinical, early-stage research, and G&A. It's a key piece of our larger strategy to reach profitability in 2027, alongside continued growth of our base business of four commercial products and investment in three successful launches for UX111, DTX-401, and GTX-102. In connection with the restructuring, we announced today a 10% reduction in our workforce, which affects roughly 130 full-time employees. Reductions in force are one of the hard parts of running a business, and we thank these colleagues for what they have given to Ultragenyx. Now I'll move to the financials. My focus will be on the full year 2025. For details on the fourth quarter, please see our press release. In 2025, total revenue came in at $673 million, which is 20% growth over 2024 and above the top end of our guidance range. Crysvita brought in $481 million, made up of $275 million from North America, $177 million from Latin America and Turkey, and $29 million from Europe. Altogether, for Crysvita, that's 17% growth over 2024, and it also came in above the top end of our guidance range. Dojolvi brought in $96 million, which is 9% growth over 2024. Evkeeza brought in $59 million, which is 84% growth over 2024, as demand keeps building after launches in our territories outside of the United States. Finally, Mepsevii brought in $37 million as we keep treating patients in this ultra-rare indication. Total operating expenses for 2025 were made up of cost of sales of $109 million and combined R&D and SG&A expenses of $1.1 billion. For the year, net loss was $575 million, or $5.83 per share. As of December 31, we had $738 million in cash, cash equivalents, and marketable securities. Moving now to guidance, I'll begin with revenue. Total revenue in 2026 is expected to be between $730 million and $760 million, which is 8%-13% growth over 2025 and leaves out potential revenue from new product launches. Crysvita revenue is expected to be between $500 million and $520 million, which covers all regions and all forms of Crysvita revenue to Ultragenyx; this range reflects growing underlying global demand, partly offset by the expected timing of ordering patterns in Brazil that we anticipate will normalize in 2027. Dojolvi revenue is expected to be between $100 million and $110 million. Now to R&D and SG&A expenses. With the strategic restructuring plan I mentioned earlier now implemented, we expect 2026 combined R&D and SG&A expenses to be flat to down low single digits versus 2025. This guidance nets the restructuring reductions from the restructuring against severance and other one-time non-recurring restructuring costs and targeted launch investments in UX111 and DTX-401. For 2027, we're projecting research and development costs will come down by 38% compared to 2025 levels — that's roughly $280 million — and the reason is that clinical and manufacturing spending on several phase III trials is wrapping up, plus we're scaling back early-stage research work. When it comes to 2027 SG&A, we anticipate that will go up to back new product launches as well as our currently approved products. If you look at R&D and SG&A together, the expectation is they'll drop by no less than 15% in 2027 relative to 2025. So with that, I'll hand things over to Erik Harris, our Chief Commercial Officer, and he'll walk you through what his team has been doing in 2025.

Erik Harris executive
#4

Thanks, Howard, and hello everybody on the line this afternoon. To get started, I'd like to build on what Emil said earlier regarding how strong and durable our commercial business already is — it keeps turning in solid results across geographies and brands. Starting back in 2017, we assembled a portfolio of 4 marketed products spanning several therapeutic areas, and every one of them keeps growing nicely while hitting or beating guidance each and every year. That reliability stems from thoughtful planning, investment made with discipline, and consistently excellent execution in some of the world's most complicated rare disease markets. Crysvita continues to be a key piece of our base business. Our collaboration with Kyowa Kirin in the U.S. is still going strong, and we keep identifying and treating commercial patients throughout Latin America and Turkey. Within Latin America, the Crysvita business has its foundation in Brazil and Argentina, alongside healthy reimbursement expansion in Mexico and Colombia over the last 12 months, which produces a meaningful revenue contribution from those nations. On top of that, we keep answering MPS requests in additional LatAm markets — evidence of rising underlying demand for this product. Credit for this steady progress goes to the considered investments we've made, combined with robust local execution. As I've said on prior earnings calls, we still anticipate a degree of revenue variability stemming from uneven ordering patterns. That shows up most clearly in Latin America, since Brazil's Ministry of Health submits the biggest orders in that region. You can see this pattern in the 2026 Crysvita guidance range Howard referenced earlier, and it factors in rising global demand growth, partly offset by the anticipated timing of ordering patterns, which we believe will normalize in 2027. Turning to Dojolvi. Now 5 years past launch, the product keeps growing steadily, with over 100 started forms in the U.S.; that marks the third year in a row. Across EMEA, we've observed ongoing MPS growth throughout the region, and we also notched 2 regulatory wins last year: early marketing authorization in Kuwait in September 2025, and approval of the early access pathway in the U.K. in April 2025. In Japan last year, we announced that Dojolvi received conditional approval, and we anticipate full approval along with the launch of the product in Japan during the second half of 2026. Last, Evkeeza, which stands as another compelling example of how Ultragenyx can generate growth in a comparatively small market via relentless patient identification and effective commercialization pathways. We only started commercializing in our territories outside the U.S. with formal reimbursement approvals within the last couple of years. Throughout the EMEA region, we now have patients on reimbursed therapy in all, nearly all major markets, with roughly 350 patients spanning 20 countries receiving Evkeeza as of today; in December, we hit a major milestone when Evkeeza was registered in the Kingdom of Saudi Arabia, underscoring our dedication to delivering life-changing therapies to patients around the world. We've additionally brought Evkeeza to market in Japan, and since that first launch back in January 2024, the momentum there has been steady and sustained. That puts us in position both to roll out more new products in Japan and to use it as a base for wider commercialization chances across APAC. As time goes on, we anticipate Evkeeza will keep expanding in a meaningful way and contribute to our growing revenue base. To wrap up, we head into 2026 with a commercial infrastructure that's proven and a seasoned team that executes with discipline and precision time and again as we bring complex rare disease therapies to patients around the world and scale them. With two possible gene therapy launches on the horizon and pivotal Angelman data coming, we're well-prepared and confident about delivering the next phase of growth needed to reach profitability. So with that, I'll hand the call over to Dr. Crombez to walk through the clinical and regulatory milestones for the year ahead.

Eric Crombez executive
#5

Thanks, Eric, and good afternoon to all of you. I'll take a few minutes to walk through the clinical and regulatory catalysts we see coming in 2026. Let me begin with DTX-401, which is for treating glycogen storage disease type Ia. Our rolling BLA submission wrapped up at the close of December, and we're looking for a PDUFA action date during the third quarter of this year. Turning to UX111, for Sanfilippo syndrome type A. At the World Symposium, we recently shared the encouraging long-term data that Emil referenced earlier on this call. Regarding the IRL that came in earlier today, our manufacturing and regulatory teams are working urgently to supply the detailed supportive documentation needed so we can resubmit our BLA as fast as possible, given how critical this life-changing therapy is. As for UX701, which treats Wilson disease, we finished enrolling the five patients in the fourth dosing cohort last year, and we anticipate sharing data across all four cohorts later this year. Finally, GTX-102, for Angelman syndrome. We're still treating patients in the 48-week ASPIRE study and still enrolling patients in the supportive AURORA study. We expect to share ASPIRE phase III data during the second half of 2026. With that, I'll hand the call back to Emil for some closing remarks.

Emil Kakkis executive
#6

Thanks, Eric. Through the strategic restructuring plan that we unveiled today, our resources and energy are being directed toward the greatest-value opportunities across our commercial and development portfolio. Patients and investigators taking part in our clinical studies worldwide will receive support from the development team, which will also work through the two BLA submissions and get ready to read out phase III data from the Angelman study. Meanwhile, geographic reach for our four commercial products will keep growing through the commercial team's efforts, and that team will prepare to launch three more programs. All of this carries forward our mission of leading the future of rare diseases with first-ever treatments. With that said, let's turn to your questions. Operator, please give the Q&A instructions.

Joon Lee analyst
#7

Hello, and thank you for allowing us to ask. For the phase III Angelman trial, the main measure is Bayley-4 cognition, whereas Ionis chose the expressive communications sub-domain. Did you pick cognition rather than expression or expressive communication because success seemed more likely, or because it ranks higher on parents' desirability or priority list? Also, could you tell us the share of patients finishing phase III who chose to continue into the long-term extension part of the study? Thanks.

Emil Kakkis executive
#8

Yes. Bayley cognition represents a foundational activity, and incidentally, communication cannot exist without cognition either. These things are completely interwoven. Communication certainly matters, yet it requires more time. It must grow and mature, and although we are assessing expressive communication within our program and will generate data on that, we concluded it did not make sense as a primary endpoint, because of its heterogeneity and the complexities involved in its development. That said, our trial won't rely solely on Bayley's cognition; we've also directed a portion of the study's power toward the Multi-Domain Responder Index, yielding a blend of cognition, receptive communication, sleep, behavior, and motor function, offering a wider assessment that matters greatly to parents too. Thus we believe the combination we have will deliver crucial insight into how their patients are progressing. It will matter for both patients and doctors, and we'll incorporate all information, even items concerning expressive communication; as for your second question about rolling over, we saw extremely few dropouts in our program — I don't even recall the count. Everybody stayed on treatment. Eric, I don't know whether you'd like to add anything about the extension or patient rollover.

Eric Crombez executive
#9

Yes, it’s along the lines of what we observed in phase I and phase II. In the phase III studies, retention has been extremely strong, and that includes patients who choose to keep going in a long-term extension study. I believe parents genuinely recognize that this gives their kids a chance to grow, develop, and pick up new abilities — things that you wouldn’t observe through natural history.

Maury Raycroft analyst
#10

Hello, and thank you for letting me ask. I have another one about Angelman as well. Now that enrollment is complete, I was hoping you could expand on how the baseline profile of these patients compares with those enrolled in your Phase I and Phase II studies, and which particular baseline parameters do you think will affect how the control arm performs on cognition? Also, what is your current expectation regarding what you can demonstrate on cognition in both the treatment arm and the control arm?

Emil Kakkis executive
#11

Sure. As you may recall, Maury, during our phase II trial we ran an expansion study; the purpose there was to examine 8 countries in which the phase III would be conducted. So the idea behind it was to add 50 patients and possibly assess phase III-type patients drawn from every one of those countries. The baseline information we observed and shared for cohorts A and B, the ones outside the U.S., closely mirrors what we are now seeing in our phase III program; therefore we feel at ease with it. What we observe in phase III matches what the expansion program showed us, and that was the whole reason for the expansion — at minimum it gave us an idea of the wider population across many countries, rather than only the U.S. As for cognition and control, our assumption is that cognitive change on the Bayley will be no more than 1 point in either the natural history group or the randomized control phase. This is an extremely stringent measure; moving it is very difficult. It isn't the kind of thing that lends itself to a placebo effect. We are being extremely careful about how this is carried out, and wherever we can, we actually use a central firm that supplies the testers for the Angelman patients in our trial; that supports the quality and consistency of the assessments, so they are administered in a highly uniform manner. So we are fairly confident that whatever change appears in the control group will be minimal. We don't anticipate much of a placebo effect, though naturally variation always exists; this is neurology, and we believe our study is sized appropriately to help handle that variation; in addition, we have incorporated the Multi-Domain Responder Index, which provides us a further chance to examine these patients more broadly and with greater power.

Maury Raycroft analyst
#12

Understood, that clears things up. I appreciate you answering my questions.

Priyanka Nagpal executive
#13

Hey everyone, Priyanka here filling in for Anupam. Could you give us additional detail on the path Ultragenyx intends to follow to reach profitability in 2027, given that burn during 2025 came to roughly $466 million? Also, please remind us of the number of drug launches that will feed into the 2027 top line.

Emil Kakkis executive
#14

Alright, Howard covered a few points regarding significant expense decreases happening because of how programs are advancing. In a moment, I’ll have him walk you through the specifics. How the base business grows will play a major role in the outcome we reach. There’s definitely a possible boost coming from the other areas as well. Howard, perhaps you could add a bit more, or restate some of the clear picture around how we’re shifting in the direction of profitability.

Howard Horn executive
#15

Sure, glad to do that. Let me walk through it right now. I should also point out that a page or two covering this can be found in our corporate deck, should you wish to look at it afterward. Our route to profitability, though, rests on several assumptions. On the top line, as Emil said, we assume ongoing expansion at a double-digit rate from the products we have now, along with a boost from certain launches still to come. Turning to costs, as I said a short while ago, for 2026 we ought to see R&D and SG&A taken together come in flat to down low single digits compared with 2025, and for 2027 that combined figure should decline by 15% or more. Within our cash plan, we have the $735 million we flagged today. We're also looking at two PRVs as part of how we intend to reach profitability. Perhaps I should add that, while we're in launch mode, certain PNL dynamics are worth keeping in mind too — for instance, R&D trends, or rather, it often gets lower because manufacturing costs are capitalized after approval. Gross margins, likewise, often run higher since pre-approval inventory being sold during launch was previously expensed. Those are a few dynamics to bear in mind as you work through your modeling. I think that's where I'll leave it.

Emil Kakkis executive
#16

Also, I believe it matters that a portion of what we spend in 2026 goes toward creating that stock of products set to come out. So here's the real picture: certain costs you're bringing up right now are in fact going toward accumulating that inventory for future release. Ideally, those mixes deliver a scale of impact big enough to carry us to that point. Getting two approvals is something we need. Within our financial plan, two PRVs do exist; even so, our view is that the reductions we've made today, plus other efforts currently underway, will leave us well positioned to remain profitable in 2027.

Will Soghikian analyst
#17

Hi everyone, Will Soghikian here, filling in for Joseph Schwartz. We appreciate you taking our question. I've got one about Angelman, followed by a brief second question. Regarding GTX-102, your company has said all along that this is the most potent ASO currently being developed; we'd like to know whether that assertion rests on UBE3A knockdown, or instead on mRNA or protein increases seen preclinically? Also, could you remind us what kind of relationship has been observed between knockdown and protein expression? Then I have a short follow-up. Thanks.

Emil Kakkis executive
#18

Well, clearly, you can only track knockdown and expression in an animal model, correct? Since brain biopsies aren't something we perform on patients, right? So to be clear, those estimates have to come from non-human primates; now, since our ASO matches the non-human primate sequence, we're able to run an experiment in the non-human primate, for instance, that Ionis cannot run because they lack homology in non-human primate; so our experiments in non-human primate have demonstrated that we knock down the antisense transcript substantially throughout the brain and induce UBE3A expression. And we accomplish this at levels of roughly 1 to 2 milligram dosing across a few doses. So a fairly low dose that would translate into humans in the range of 10, let's say, 10 to 14 milligrams. We also know now, based on our ASPIRE presentation last year, that we demonstrated an effect on Bayley cognition and other endpoints, and that Ionis demonstrated a comparable effect on Bayley cognition over a 6-month timeframe, although they didn't demonstrate our higher level of benefit over time. That is occurring at doses in our study within the 5 to 14 range, whereas they use 40 to 80 milligrams, and Roche used even higher doses. We're achieving comparable Bayley cognition at substantially different doses. That substantiates what we found in non-human primates previously, that what we predicted held true and that the effect we observe in our primates translates to humans with a potent effect at a lower dose level.

Will Soghikian analyst
#19

Excellent. Many thanks. And if I could, only one brief additional question. As I recall, enrollment for the DTX-301 program wrapped up roughly 12 months back at this point. So I was simply curious whether you might provide a brief status report regarding how that is progressing. Thanks.

Emil Kakkis executive
#20

Sure; the DTX-301 program, a gene therapy aimed at ornithine transcarbamylase, also known as OTC, has its phase III still ongoing, and we anticipate releasing data tied to the ammonia endpoint at some point during this year.

Will Soghikian analyst
#21

Excellent. Many thanks.

Rick Miller analyst
#22

Hello, I'm Rick Miller, filling in for Kristen. We appreciate you fielding our questions. Regarding the IRL that was received for UX111, would you say the problems brought up were in line with what you anticipated? Can you share any perspective on that? And then, taking a wider view of the gene therapy pipeline, what should we understand about how the strategic restructuring affects your priorities in that area, if it does at all?

Emil Kakkis executive
#23

Yes; so concerning the IRL, the set of concerns on the CRL is familiar to both sides, to FDA and to us. Clearly, our list matched theirs, but the real question becomes, what do you include in the package? And what we included were responses addressing how we're managing each item, updates to SOPs, CAPA agreements, activities we're undertaking — we included all of that so they could see everything. They actually want every piece of supporting documentation, such as the SOPs and the effectiveness follow-ups, and so on, which typically we wouldn't consider something that belongs in a BLA, yet the FDA has asked us to supply these. We feel we possess the responses to what they've asked for. I think these matter, no doubt, and we've dealt with them previously, but we'll give them the complete documentation, which is a considerable volume, yet we'll deliver complete documentation as quickly as possible in a resubmission for the BLA; as for the restructuring and the gene therapy pipeline, clearly we have a significant presence in gene therapy with 2 gene therapies right at the BLA stage, at this moment. We have a third gene therapy, OTC, which is in phase III, plus a fourth for Wilson disease that is currently in phase II; we have yet another IND stage program for CDKL5 that is sitting on the sidelines; with the restructuring, our hope had been to advance one additional gene therapy into the clinic, but at present, the primary goal is to get what we already have in play, their late stage, out and approved. That created the opportunity for us to then do more. We don't intend to shrink our future in gene therapy, but we don't intend for our future to consist solely of gene therapy; so although we have one more gene therapy program, we also have two other INDs, for instance, that are ready to go; they aren't gene therapy because we do want to be a diversified company and don't want to be concentrated in a single area. So the restriction will in fact allow us to bring more of our early stage programs into play as we wrap up our phase III programs. We'll keep doing some work in gene therapy, but it won't be the sole focus for our pipeline moving forward.

Allison Bratzel analyst
#24

Hi, thank you for fielding my question. This should be pretty brief. Turning back to setrusumab, I believe you had earlier floated a theory that ORBIT failed to hit its endpoint because those receiving treatment were feeling improved, grew more physically active, and therefore faced a higher chance of fracture. Now that you're examining the data further, I'm wondering, do you observe a distinct link between higher activity levels and the rate of fractures among those on the treated arm, which would back up that account? Or can that theory be confirmed in some manner? Further observations along these lines would be welcome.

Emil Kakkis executive
#25

As we mentioned, our deep assessment of the data is ongoing. Our earlier presentation demonstrated that in ORBIT, the group given setrusumab showed gains in reported activity and function, along with reduced bone pain. So it's evident they did feel improved and were engaging in more. Pinpointing exactly how that leads directly to refractures is a matter we're investigating. There is nothing we can share at this time. The evaluation continues at this moment, yet the data does point toward patients reporting enhanced physical function and diminished bone pain, which aligns with that; however, we keep analyzing the program's data, and additional details will come once a conclusive response regarding the program has been reached.

Lydia Edelman analyst
#26

Hello, Lydia here, filling in for Salveen. We really appreciate you answering our questions. Perhaps one more regarding Angelman, continuing from an earlier inquiry. Since your endpoint differs from the one Ionis is using, what would the regulatory threshold be, and how sure are you that it's essentially already set as you move forward? Thank you.

Emil Kakkis executive
#27

Yes, I'm aware plenty of folks are highlighting the distinctions. My view is actually that the two programs share quite a few endpoints in common. Ultimately, no matter which is primary or secondary, when you discuss the commercial side, everything gets examined. The commercial outlook won't be determined simply by which endpoint is chosen. The regulatory threshold comes from the pharmaceutical design in this case—essentially a randomized sham-controlled study featuring a continuous variable analysis of Bayley cognition. The FDA recognizes our belief that the clinical benefit magnitude sits at roughly 5 or 6 points, yet that isn't incorporated into the primary endpoint. Basically, we're seeking a continuous variable change. What we do know is that we can detect shifts of single-digit size. Certain patients achieve improvements in the double-digit range. So the range of response varies. We've shown this previously regarding how they respond. Our hope is to show a statistically significant, clinically meaningful cognitive change—the same thing we saw in the A and B cohorts and shared before—and that this will be enough for approval; beyond that, we also expect other endpoints to succeed, and the Multi-Domain Responder Index represents our approach to viewing the disease more broadly and capturing greater benefit; from the FDA's perspective, it's a novel form of endpoint analysis. Even so, they've permitted us to include it with an alpha allocation. We genuinely see it as a path forward for neurology involving heterogeneous diseases, and that threshold is one we establish for every endpoint according to what counts as clinically meaningful change or the minimum shift regarded as important for a disease. Those matters we discuss with the agency—establishing them and reaching mutual understanding—will yield validation data from the phase III trial to help support the regulatory threshold of a responder for the MDRI; thus, combining both elements—the key variable analysis, Bayley cognition, plus the minimally important difference-driven changes in the MDRI—will deliver what we consider clinically important and regulatory sufficient data to secure a filing for this disease, provided the trial succeeds.

Lydia Edelman analyst
#28

Thank you very much.

Steven Ionov analyst
#29

Steven Einhorn here, filling in for Yaron. We appreciate the update and the guidance. A few questions from our side. There are two PRVs that could come our way in 2026. Do you have any view on how quickly monetization might happen, if everything proceeds as hoped, and do you intend to reach out to prospective purchasers in advance? Perhaps you could refresh us on the schedule. Then, turning to the UX701 program, I believe you had said before that an update would come in the first half of this year regarding the cohort receiving the highest dose, plus the earlier cohorts too. With the full year 2026 timeline now in play, is that slipping to a later point, or are we interpreting that incorrectly? Thanks.

Emil Kakkis executive
#30

Correct. Regarding those two PRVs, the initial thing is that approval has to be secured for both products, which is what triggers issuance of the PRV. Howard, would you like to say something about where we stand on the timeline for handling PRVs and their sale?

Howard Horn executive
#31

Sure, my take would be that we'd turn those into revenue without delay, and whether that happens beforehand through an option agreement or in the usual fashion once they've come into our possession is still up in the air.

Emil Kakkis executive
#32

Okay, so regarding the Wilson program, when our data comes in really hinges on the rate at which patients are improving. Our view is that a minimum of 6 months is necessary, and in our initial cohorts, what we previously presented was roughly 6 to 8 months to demonstrate a sufficient impact on copper. So we are simply giving less exactness around that timing, which allows us the chance to keep observing what happens with those patients. This isn't intended to be some major shift. We're only being less specific because we want to monitor how these patients fare on the higher dose we've given. We also need to ensure there's adequate time for their standard of care to be withdrawn, should they reach the appropriate copper context. It's merely a bit less precision, not a basic alteration.

Analyst analyst
#33

All right. That's probably my turn. Hey, everyone. There are a couple of things I'd like to ask. To start, could you make it clear — and apologies if this was covered before I joined — regarding an IRL, once you resubmit, what review timelines toward a final decision are possible starting from the moment you send back the responses the agency has requested? Then, a question about 401 for GSDIa. Any fresh thinking on how pricing might shape up there? Also, do you have a view on what sort of launch trajectory we should expect? Would it be gradual and steady, or might it be steep right away? Thanks.

Emil Kakkis executive
#34

Great. Regarding the IRL timeline, what we just sent in was a resubmitted BLA addressing the CRL we got. What's going on here is that we essentially have to resubmit that resubmission. So the timeline mirrors what we had previously. We would send it back with the extra information now incorporated into the BLA, and we'd anticipate roughly a couple of weeks for them to figure out whether it contains all the document pieces they're looking for. After that, a PDUFA date would then be established approximately six months following the original submission. So as for the question of how long it takes to reach that point, we haven't yet settled how long it takes us to assemble the documents and submit them, but we're working diligently to put that together. Now, your other question concerning the GSDIa launch, is that right? And-

Analyst analyst
#35

Yes, correct. Yeah, that is correct.

Emil Kakkis executive
#36

Yeah. In the case of GSDIa, this is an extremely critical illness, given that those affected consume starch every 120 minutes, throughout the entire day and through the whole night, correct? So there is substantial urgency; our expectation would be considerable interest from the start, though I'd say that market will likely grow somewhat more gradually, as an example, than IIIA, MPS IIIA, in which patients face an urgent situation and absolutely need treatment right away to try to prevent brain loss. Right? So MPS IIIA will probably occur with greater urgency than GSDIa, yet we do anticipate strong, consistent demand, though I wouldn't anticipate it being all at once initially. Now, regarding GSDIa, no pricing has been established by us at all, but we have discussed a range of $1 million-$2 million for pricing, while for MPS IIIA, a range of $2 million-$4 million has been discussed by us.

Maxwell Skor analyst
#37

Thanks. I appreciate you fielding my question. Turning to the ASPIRE study, could you explain how sites are trained so that Bayley-IV administration stays uniform? Also, when you give this assessment to older pediatric patients rather than younger ones, do any practical issues or extra complications come up? Thank you.

Emil Kakkis executive
#38

Thank you. That's quite a granular technical question, yet a meaningful one, since how the Bayley is conducted matters a great deal. To begin with, our company has consistently placed greater weight on endpoint design, valuation, and training than nearly any other company. An entire department handles this work you're referring to — the Endpoint Development Strategy group, or EDS group. A senior PhD leads that group, and it includes a set of PhDs who are essentially experts in trial design, endpoint design, plus training and evaluation. So we built a thorough training program for every site. Beyond that, for Bayley cognition and Bayley scores in particular, at as many sites as possible, we brought in a centralized company to handle Bayley scoring using experts who understand Angelman and know how to administer a Bayley to an Angelman patient. At the greatest number of sites we can manage, we're supplying those testers to help ensure the quality and consistency of the Bayley evaluation. Alongside our own training program, we believe this will introduce a considerable degree of consistency into what we're doing. Still, you're correct that this area matters greatly, and we've taken many steps toward it. I'd add that I doubt any other company has a department of people who actually perform this very activity. So I want to thank Dr. Schreiner, who leads our group, for all her efforts in assembling this for our Angelman program. Getting it done required substantial work from her and her team.

Maxwell Skor analyst
#39

Great, thank you.

Yigal Nochomovitz analyst
#40

Yes, hello, and thanks. I've got a quick follow-up regarding OTC. Could you elaborate a bit further on that particular study? It isn't one you discuss very often. Is it perhaps somewhat less prominent within your expectations regarding the likelihood of success? And what would have to happen for that study to succeed? Then, regarding the IRL, Emil, you said a number of those requests would have taken place during an inspection otherwise. So does that imply the inspection would be restricted, wouldn't happen, or would look different? Thank you.

Emil Kakkis executive
#41

Okay, regarding the OTC program in phase III — we always attempt to prioritize what we talk about, and there are just so many programs we have. Putting everything out there about every single thing happening is certainly a load on everybody. Still, it exists, and it keeps moving forward. OTC, in my view, is a genuinely significant disease with a very serious need for improved therapies. What we have is that phase III trial, which I believe randomized roughly 37 patients, and the endpoint we'd be examining involved the shift in ammonia levels comparing treated subjects with controls. That ammonia measurement in the study — people's ammonia varies. A few are normal when they start, a few are elevated; we're asking whether we manage ammonia more effectively, and that serves as the primary endpoint for the blinded part of the study. After that, in the study's second part, we'll examine whether patients are able to come off standard of care, or how successfully they come off standard of care. This is a meaningful program, though it isn't our number one priority, so we continue to pursue it. We'll obtain the data. It provides another chance for us as a company, another valuable asset available down the road, and we'll report data on it during this year. As for the IRL, I, I have zero doubt the FDA will arrive and inspect, as they properly should. I believe supplying the documentation gives them stronger confidence right away that we genuinely have completed everything they're asking for. We've laid out the responses and what we've done, but what they really want is to see the actual materials behind the things we've done, correct? Not merely explain adjustments to SOPs, but actually show me the SOPs, etc., and every element connected with that. These were requests that matter in building a quality manufacturing program; the work has been completed by us, so now we'll give them a more thorough, fuller set of supporting documentation, which, incidentally, is an extremely large amount of information, plus a great many documents. But we'll hand it over to them in advance so they can confirm that we have finished everything they've requested.

Yigal Nochomovitz analyst
#42

Thank you.

Luca Issi analyst
#43

Oh, great. Yeah, I really appreciate you taking the time for my question. So Emil, perhaps if we step back and look at the FDA from a broader perspective. What was your take on that REGENXBIO CRL that came out a few days ago? From what it sounds like, the FDA has certain concerns regarding the use of serum biomarker rather than natural history in the context of ultra-rare disease. Is this simply an isolated case tied to their particular program, or have we reached the point where this FDA has effectively set a higher hurdle for every company working on therapies for rare and ultra-rare diseases? Again, I'd be glad to hear anyone's thoughts on that — thank you very much. And then maybe a quick one for Howard. With your 2026 revenue guidance of $730 million to $760 million, how does the simple rough math work out, or how much of that amount is cash as opposed to non-cash? Thanks a lot.

Emil Kakkis executive
#44

All right. Thank you. As for the situation with REGENXBIO — well, we said in our script today that the heparan sulfate data presented at the Reagan-Udall meeting definitively establish a relationship, and that measuring heparan sulfate in spinal fluid can be done using several different methods that produce very similar response patterns and, in my view, are equally predictive. Based on that FDA decision, it looks like there's been a stronger pushback against the biomarker. During our review, we also saw more weight placed on our clinical endpoints rather than the biomarkers. Even so, our position is that these biomarkers capture what's actually driving the disease, giving us a reliable means of gauging both the illness and how well a treatment works, and we'll keep backing them in front of the FDA and in public. Is the FDA resisting? Their stance seems less accepting of the biomarkers than what everyone signed off on at the Reagan-Udall meeting. They've made public statements indicating they back accelerated approval and products for rare diseases. What matters now is seeing those words translate into real steps for everyone who needs these therapies — people facing conditions such as Hunter syndrome, which REGENXBIO is developing treatments for, plus Sanfilippo and other neurologic disorders that still have no approved option at all. Biomarkers serve as a truly vital tool for understanding exactly what effect you're having and how well it's working. Even though there could be resistance and the standard might get tougher, it's important for the FDA to understand patient needs and to recognize the science supporting the biomarkers we selected, including why these are valuable for assessing disease and forecasting the right clinical results.

Sami Corwin analyst
#45

Hello, and thank you for taking my question. I suppose what I wanted to know is what assumptions you have internally regarding a possible sale of the priority review vouchers, and whether the recent renewal of the rare pediatric disease, PRV legislation altered those assumptions in any way. And then, how significantly might a shift in price affect your route to profitability in 2027? Thanks.

Emil Kakkis executive
#46

All right; so you have that PRV and path to profitability. Howard, you know, we simply didn't respond to that other question I just spotted on the-

Howard Horn executive
#47

Yeah. We'll follow up. We'll follow up with Luca offline on that one.

Emil Kakkis executive
#48

All right.

Howard Horn executive
#49

Where PRVs are concerned, though, the recent outcome wasn't what our models had assumed — in other words, the $200 million range wasn't part of our modeling. What we had built in was a figure somewhat above $100 million. Seeing the legislation approved again left us quite thrilled. In our view, that opens the door not just to the two PRVs already referenced for the gene therapies, but also for 102 and for additional programs down the road. And at present, that base modeling assumption of ours remains just above $100 million. Consequently, whatever comes in above that amount would boost our balance sheet.

Sami Corwin analyst
#50

Understood, thanks.

Joshua Higa executive
#51

Appreciate it. That wraps up the call for today. Should any further questions come up, feel free to reach out to us either by phone or at ir@ultragenyx.com. Thanks for being with us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ultragenyx Pharmaceutical Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ultragenyx Pharmaceutical Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.